LIFEVANTAGE CORP Business Development
LIFEVANTAGE CORP (LFVN) reported Business Development of -$695.00 thousand for the 12-month period ending 2013-06-30, per its 10-K filed 2013-09-12.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessDevelopment · last filed 2013-09-12
- LIFEVANTAGE CORP business development for the quarter ending 2013-06-30 was -$332.00K.
- LIFEVANTAGE CORP business development for the quarter ending 2013-03-31 was -$363.00K.
- LIFEVANTAGE CORP business development for the quarter ending 2012-06-30 was $0.00.
- LIFEVANTAGE CORP business development for the quarter ending 2012-03-31 was $0.00.
- LIFEVANTAGE CORP business development for fiscal 2013 was -$695.00K.
- LIFEVANTAGE CORP business development for fiscal 2012 was $0.00.
- LIFEVANTAGE CORP business development for fiscal 2011 was $0.00.
| Period end | Business Development 3 month | Business Development 6 month | Business Development 9 month | Business Development 12 month |
|---|---|---|---|---|
| 2013-06-30 | -$332.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-09-12 | -$695.00K derived: sum of 2 quarters · filed 2013-09-12 | -$695.00K 10-K · filed 2013-09-12 | |
| 2013-03-31 | -$363.00K 10-Q · filed 2013-05-09 | -$363.00K 10-Q · filed 2013-05-09 | ||
| 2012-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-09-12 | $0.00 derived: sum of 2 quarters · filed 2013-09-12 | $0.00 10-K · filed 2013-09-12 | |
| 2012-03-31 | $0.00 10-Q · filed 2013-05-09 | $0.00 10-Q · filed 2013-05-09 | ||
| 2011-06-30 | $0.00 10-K · filed 2013-09-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |